262 related articles for article (PubMed ID: 24032262)
21. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of CD133 expression in Endometrial Cancer Patients.
Mancebo G; Sole-Sedeno JM; Pino O; Miralpeix E; Mojal S; Garrigos L; Lloveras B; Navarro P; Gibert J; Lorenzo M; Aran I; Carreras R; Alameda F
Sci Rep; 2017 Aug; 7(1):7687. PubMed ID: 28794448
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study.
Chao X; Wu M; Ma S; Tan X; Zhong S; Bi Y; Wu H; Lang J; Li L
Sci Rep; 2020 Apr; 10(1):5984. PubMed ID: 32249826
[TBL] [Abstract][Full Text] [Related]
24. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma.
Tang Q; Jiang X; Li H; Lin Z; Zhou X; Luo X; Liu L; Chen G
J Obstet Gynaecol Res; 2011 Jun; 37(6):606-12. PubMed ID: 21564416
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
27. Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer.
Wilczynski M; Danielska J; Domanska-Senderowska D; Dzieniecka M; Szymanska B; Malinowski A
Acta Obstet Gynecol Scand; 2018 May; 97(5):560-569. PubMed ID: 29355888
[TBL] [Abstract][Full Text] [Related]
28. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
29. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
30. Preoperative Anemia as a Prognostic Factor in Endometrioid-Type Endometrial Carcinoma.
Abu-Zaid A; Alsabban M; Abuzaid M; Alomar O; Salem H; Al-Badawi IA
J Obstet Gynaecol Can; 2018 Nov; 40(11):1393-1400. PubMed ID: 30473117
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
[TBL] [Abstract][Full Text] [Related]
32. S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
DeRycke MS; Andersen JD; Harrington KM; Pambuccian SE; Kalloger SE; Boylan KL; Argenta PA; Skubitz AP
Am J Clin Pathol; 2009 Dec; 132(6):846-56. PubMed ID: 19926575
[TBL] [Abstract][Full Text] [Related]
33. RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.
Liu S; Lin M; Ji H; Ding J; Zhu J; Ma R; Meng F
Diagn Pathol; 2019 Jan; 14(1):7. PubMed ID: 30684972
[TBL] [Abstract][Full Text] [Related]
34. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
36. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.
Yang B; Shan B; Xue X; Wang H; Shan W; Ning C; Zhou Q; Chen X; Luo X
PLoS One; 2016; 11(5):e0155145. PubMed ID: 27163153
[TBL] [Abstract][Full Text] [Related]
37. The frequency and significance of WT-1 expression in serous endometrial carcinoma.
Hedley C; Sriraksa R; Showeil R; Van Noorden S; El-Bahrawy M
Hum Pathol; 2014 Sep; 45(9):1879-84. PubMed ID: 25033726
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study.
Salvesen HB; Iversen OE; Akslen LA
J Clin Oncol; 1999 May; 17(5):1382-90. PubMed ID: 10334522
[TBL] [Abstract][Full Text] [Related]
39. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
40. [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
Pozharisskiĭ KM; Samsonova EA; Ten VP; Maksimova NA; Urmancheeva AF
Arkh Patol; 2005; 67(2):13-7. PubMed ID: 15938112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
